Unlabelled: Preclinical and clinical work suggests that mifepristone (glucocorticoid receptor antagonist), may be a viable treatment for alcohol use disorder (AUD). The aim of this work was to translate our preclinical mifepristone study using yohimbine (α2 receptor antagonist) stress-induced reinstatement of alcohol-seeking to a clinical setting. This was a Phase 1/2, outpatient, cross-over, randomized, double-blind, placebo-controlled trial with non-treatment-seeking individuals with AUD ( =32). We investigated the safety, alcohol craving and consumption after oral administration of mifepristone (600mg daily for a week) in a human laboratory study comprised of administration of yohimbine in a cue-reactivity procedure and alcohol self-administration. Outcomes were assessed using Generalized Estimating Equations and mediation and moderation analyses assessed mechanisms of action and precision medicine targets. We did not observe serious adverse events related to the study drugs or study procedure and mild to moderate non-serious adverse events were reported by both study conditions. Also, there was no statistically-significant difference between the mifepristone and placebo in the hemodynamic response, alcohol subjective effects and pharmacokinetics parameters. Mifepristone significantly reduced alcohol craving and increased cortisol levels. Mifepristone-induced cortisol increase was not a mediator of alcohol craving. Moderation analysis with family history density of AUD (FHDA) and mifepristone, suggested that reduced craving was present in individuals with , but not FHDA. Mifepristone, compared to placebo, did not reduce alcohol consumption in the laboratory or in a naturalistic setting. This study successfully translated a preclinical paradigm to a human laboratory study confirming safety, tolerability and efficacy of mifepristone in an alcohol paradigm. Mediation analysis showed that the effect of mifepristone on craving was not related to mifepristone-induced increases in cortisol and moderation of FHDA suggested the importance of evaluating AUD endophenotypes for pharmacotherapies.

Clinical Trial Registration: Clinicaltrials.gov ; NCT02243709.

Ind/fda: 121984, mifepristone and yohimbine (Holder: Haass-Koffler).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882427PMC
http://dx.doi.org/10.1101/2023.01.02.23284122DOI Listing

Publication Analysis

Top Keywords

alcohol craving
16
mifepristone
11
alcohol
9
receptor antagonist
8
human laboratory
8
laboratory study
8
adverse events
8
fhda mifepristone
8
study
7
craving
6

Similar Publications

In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years.

View Article and Find Full Text PDF

Background: Alcohol use among emerging adults is a public health concern, as it has been associated with numerous negative consequences. Poor sleep has repeatedly been associated with alcohol-related consequences in this age group, yet factors impacting this relationship and potential moderators remain largely unexplored.

Objectives: The primary objective of this study was to examine the indirect effect of poor sleep quality on alcohol-related consequences through alcohol craving and to determine whether depression moderates this association.

View Article and Find Full Text PDF

Introduction: Ecological momentary assessment (EMA) is popular in smoking research to study time-varying processes and design just-in-time personalised cessation interventions. Yet, research examining the psychometric properties of EMA and user experiences with EMA protocols is lacking. We conducted a mixed-methods study to test the EMA component of a mobile intervention for middle to late-aged adolescents (16-20 years) who smoke cigarettes at least weekly.

View Article and Find Full Text PDF

Insomnia is prevalent among patients with alcohol use disorder (AUD), potentially undermining treatment and increasing the risk of relapse. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia, but its efficacy is not well-characterized in patients across the spectrum of AUD. The aim of this meta-analysis was to quantify the effectiveness of CBT-I in improving insomnia severity and alcohol-related outcomes in adults with heavy alcohol use and/or varying levels of AUD severity and comorbid insomnia.

View Article and Find Full Text PDF

Background: Advancing evidence-based, tailored interventions for substance use disorders (SUDs) requires understanding temporal directionality while upholding ecological validity. Previous studies identified loneliness and craving as pivotal factors associated with alcohol consumption, yet the precise directionality of these relationships remains ambiguous.

Objective: This study aims to establish a smartphone-based real-life intervention platform that integrates momentary assessment and intervention into everyday life.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!